Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
Baohuoside I
Cat. No.:
0225LY-1149
Appearance:
Solid
Purity:
≥98%
Identity:
Confirmed by NMR, and LC-MS.
Size:
Add to basket
Product Overview
Description:
Baohuoside I is a constituent of Epimedium koreanum that displays anti-osteoporosis and anti-inflammatory properties.
Synonym:
Icariside-II; Icariin-II; 113558-15-9; 5,7-dihydroxy-2-(4-methoxyphenyl)-8-(3-methylbut-2-enyl)-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxychromen-4-one; 4H-1-Benzopyran-4-one, 3-[(6-deoxy-alpha-L-mannopyranosyl)oxy]-5,7-dihydroxy-2-(4-methoxyphenyl)-8-(3-methyl-2-buten-1-yl)-; Baohuoside-I; 5,7-Dihydroxy-2-(4-methoxyphenyl)-8-(3-methylbut-2-en-1-yl)-3-(((2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-4H-chromen-4-one
CAS No.:
113558-15-9
Compound CID:
5488822
Formula:
C27H30O10
Formula Weight:
514.52
Specification
Relative Density:
1.46 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
Baohuoside I can be used in cancer biology to study its anti-tumor effects and its role in modulating various signaling pathways.
Library Information
Target:
CXCR
Receptor:
CXCR4
Pathways:
Autophagy; GPCR/G protein signaling; Immunology/Inflammation; Apoptosis
Plate Number:
AOCL-15
Plate Location:
g5
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10mM DMSO
DMSO Max Solubility:
257.5 mg/mL; 500.47 mM
ALogP:
2.913
HBA_Count:
5
HBD_Count:
5
Rotatable Bond:
6
